4 results match your criteria: "Axon Clinical Research[Affiliation]"

Article Synopsis
  • The AZURE study was a 76-week clinical trial comparing two treatment regimens of aflibercept in patients with neovascular age-related macular degeneration, evaluating a flexible treat-and-extend approach versus a fixed dosing schedule.
  • Patients aged 51 and older who had been on aflibercept for at least a year were randomly assigned to receive either a treat-and-extend regimen or fixed dosing every 8 weeks, with changes monitored based on visual acuity and anatomical results.
  • Results showed that both regimens produced similar changes in best-corrected visual acuity, with high rates of vision maintenance, and the treat-and-extend approach allowed for longer intervals between treatments for some patients without any new safety concerns.
View Article and Find Full Text PDF

Introduction: Hypoactive sexual desire disorder (HSDD) is the most common sexual complaint in women. Currently there are no validated instruments for specifically assessing HSDD severity, or change in HSDD severity in response to treatment, in premenopausal women. The Sexual Interest and Desire Inventory-Female (SIDI-F) is a clinician-administered instrument that was developed to measure severity and change in response to treatment of HSDD.

View Article and Find Full Text PDF

A common practice in depression trials is to exclude patients whose depressive symptoms improve between Screen and Baseline evaluations under the assumption that they are more likely to respond to placebo. The present study investigated this contention by examining the relationship between pre-randomization changes in Hamilton depression rating scale (HAMD) scores to post-randomization placebo response and drug-placebo separation. Four randomized, double-blind, placebo-controlled trials (active medication=fluoxetine or paroxetine) were conducted in outpatients with Major Depressive Disorder using a novel design in which a depressive severity inclusion criterion (HAMD >/= 22) was utilized only at Screen.

View Article and Find Full Text PDF

Although the Hamilton Depression Rating Scale (HAMD) remains the most widely used outcome measure in clinical trials of Major Depressive Disorder, the psychometric properties of the individual HAMD items have not been extensively studied. In the present paper, data from four separate clinical trials conducted independently by two pharmaceutical companies were analyzed to determine the relationship between scores on the individual HAMD items and overall depressive severity in an outpatient population. Option characteristic curves (the probability of scoring a particular option in relation to overall HAMD scores) were generated in order to illustrate the relationship between scoring patterns for each item and the range of total HAMD scores.

View Article and Find Full Text PDF